GE Healthcare and PhotoCure have inked a licensing agreement covering the Oslo, Norway-based firm's Hexvix optical molecular imaging agent for diagnosing and monitoring bladder cancer.
Under the deal, GE of Chalfont St. Giles, U.K., has gained exclusive global rights to market and distribute Hexvix outside of the U.S. and the Nordic region. The agreement also includes an exclusive option for GE to market and distribute the agent in the U.S.; Hexvix has not yet been approved by the Food and Drug Administration.
PhotoCure will be responsible for manufacturing and Nordic distribution of the product. GE said the agreement also includes access to other indications for the product currently under evaluation and testing by PhotoCure.
By AuntMinnie.com staff writers
January 9, 2006
Related Reading
GE completes IDX purchase, January 4, 2006
GE taps King as company officer, January 4, 2006
GE promotes Koby, December 20, 2005
New MRI, CT, x-ray products pace GE's RSNA introductions, November 28, 2005
Fluorescence cystoscopy improves detection of early bladder cancer, February 7, 2004
Copyright © 2006 AuntMinnie.com
